Market Access & Health Technology Assessment Join industry executives in staying informed on the market access and HTA process in Romania. 1. Please make a general introduction to the public health sector in your country and its organization The Romanian social health insurance system is coordinated at a central level by the Ministry of Health, the…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Which are the administrations, bodies and institutions in charge of public health in your country and what are their respective responsibilities? The main administrations, bodies and institutions in charge of public health in Romania…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. What are the pricing models, processes and principles for originator drugs? The main enactment setting out the pricing models and approval procedures for medicines is Ministry of Health’s Order no. 368/2017 approving the Norms…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Price Control 1.1. How does price control at ex-factory prices work in your country? In order to obtain the maximum manufacturer price approval, the medicine’s marketing authorization holder should submit an application dossier to…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Which are the health technology assessment (HTA) evaluation bodies and their responsibilities in your country? The National Agency for Medicines and Medical Devices (NAMMD) is the main authority that performs health technology assessments (HTA)…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Have local authorities published recommendations surrounding value assessment dossiers? (If yes please add link) Following completion of the evaluation, NAMMD publishes the technical report (HTA report) on its website, in the section reserved for…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. In addition to the clinical data obtained through clinical studies please list the data required for: a. Market approval In addition to the clinical data obtained through clinical studies, in order to obtain the…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Are there any Managed entry agreements in place in your country? (If so, please list them) The Romanian legislation provides for the possibility to conclude cost-volume agreements / cost-volume-result agreements with NHIH, which will…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Which are the main actors involved in public procurement and tendering? The administrations, bodies and institutions in charge of public procurement and tendering for medicinal products in Romania are: At centralized/national level: the Ministry…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Please describe the main cost containment policies in place in your country and their fundamental principles a. Pricing and impact of generic/biosimilar approval The price of off-patent innovative medicines cannot exceed, as a rule:…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. Has an essential or priority drug list been published in your country? (If so provide the link) The list of essential medicinal products was approved by means of a Ministry of Health’s order, published…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Romania. 1. What is the definition of an orphan drug in your country? The Romanian legislation defines “orphan drug” by referring to the criteria provided for by Regulation (EC) no. 141/2000 on orphan medicinal products (“Regulation…
See our Cookie Privacy Policy Here